Search

Your search keyword '"monoclonal gammopathy of uncertain significance"' showing total 3 results
Start Over Descriptor "monoclonal gammopathy of uncertain significance" Topic bone marrow
3 results on '"monoclonal gammopathy of uncertain significance"'

1. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases.

Author

Tembhare PR, Yuan CM, Venzon D, Braylan R, Korde N, Manasanch E, Zuchlinsky D, Calvo K, Kurlander R, Bhutani M, Tageja N, Maric I, Mulquin M, Roschewski M, Kwok M, Liewehr D, Landgren O, and Stetler-Stevenson M

Subjects
Adult, Aged, Aged, 80 and over, Bone Marrow immunology, CD56 Antigen genetics, CD56 Antigen immunology, Cell Differentiation, Diagnosis, Differential, Female, Flow Cytometry, Gene Expression, Humans, Immunophenotyping, Leukocyte Common Antigens genetics, Leukocyte Common Antigens immunology, Male, Middle Aged, Monoclonal Gammopathy of Undetermined Significance immunology, Monoclonal Gammopathy of Undetermined Significance pathology, Multiple Myeloma immunology, Multiple Myeloma pathology, Paraproteinemias immunology, Paraproteinemias pathology, Plasma Cells immunology, Tetraspanin 28 genetics, Tetraspanin 28 immunology, Bone Marrow pathology, Monoclonal Gammopathy of Undetermined Significance diagnosis, Multiple Myeloma diagnosis, Paraproteinemias diagnosis, Plasma Cells pathology
Abstract

Flow cytometric (FC) enumeration of abnormal plasma cells (APCs) for diagnosis and prognostication of plasma cell dyscrasias (PCD) is challenging. We studied antigen expression in normal plasma cells (NPC) (N = 34) and APC in a series of unselected PCD (N = 59). NPC subpopulations often demonstrated CD19(-), CD20(+), CD45(-) or dim and CD56(+), an immunophenotype observed in PCD. However abnormal CD81 was only observed in APCs (APC detection sensitivity 95%; specificity 100%). We evaluated differences in antigen expression patterns among MGUS (N = 14), SMM (N = 35) and MM (N = 10), finding the combination of CD45 and CD56 helpful in differentiating MGUS from SMM and MM (p = 0.0002)., (Published by Elsevier Ltd.)

Published
2014
Full Text
View/download PDF

2. Resolution of Laryngeal Oedema in a Patient with Acquired C1-Inhibitor Deficiency. a Case Report

Author

Valentin Nădăşan and Noémi-Anna Bara

Subjects
medicine.medical_specialty, Case Report, acquired C1-inhibitor deficiency, 03 medical and health sciences, 0302 clinical medicine, Biopsy, medicine, monoclonal gammopathy of uncertain significance, laryngeal oedema, asphyxiation, Angioedema, medicine.diagnostic_test, RC86-88.9, business.industry, Medical emergencies. Critical care. Intensive care. First aid, 030208 emergency & critical care medicine, General Medicine, Emergency department, medicine.disease, Dermatology, Epinephrine, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Hereditary angioedema, emergency care treatment plan, Fresh frozen plasma, Bone marrow, medicine.symptom, Laryngeal oedema, business, medicine.drug
Abstract

Introduction Laryngeal oedema caused by acquired angioedema due to C1-inhibitor deficiency (C1-INH-AAE) is a life-threatening condition. The swelling is bradykinin mediated and will not respond to the usual treatment with antihistamines, corticosteroids, or epinephrine. Instead, kallikrein-bradykinin-targeted therapies should be used promptly to prevent asphyxiation. Case presentation A 43 years old female presented at the Hereditary Angioedema Centre reporting a one-year history of peripheral, facial, and neck oedema. Treatment with antihistamines and corticosteroids had been ineffective. Laboratory results showed complement level deficiencies and monoclonal gammopathy characterised as immunoglobulin M. An abdominal ultrasound revealed splenomegaly. A bone marrow biopsy was normal. Based on these data, the diagnosis of C1-INH-AAE associated with monoclonal gammopathy of uncertain significance (MGUS) was made. As C1-INH-AAE can present with life-threatening, standard treatment-resistant laryngeal oedema, an emergency care treatment plan was proposed, and the patient was advised to present to the emergency department (ED) with this medical letter. Based on these recommendations, three laryngeal attacks were successfully treated in the ED with recombinant human C1-inhibitor (two attacks) and fresh frozen plasma (one attack). After these episodes, the patient was prescribed prophylactic treatment with antifibrinolytics. No further angioedema attacks were reported by the patient at the 18 months follow-up visit. Conclusions Because angioedema of the upper airways is a life-threatening condition, recognising the specific type of swelling by the emergency physician is critical in providing immediate and effective treatment to reduce the associated risk of asphyxiation. C1-INH-AAE being a rare disorder, patients should have available an emergency care treatment plan with recommendations of acute treatment possibilities.

Published
2020

3. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.

Author

Martín, P, Santón, A, and Bellas, C

Subjects
*MULTIPLE myeloma, *MONOCLONAL gammopathies, *BONE marrow, *ANTIGENS, *CELL proliferation, *GENE expression
Abstract

Martín P, Santón A & Bellas C (2004) Histopathology 44, 375–380 Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis Differential diagnosis between multiple myeloma (MM), monoclonal gammopathy of uncertain significance (MGUS), and polyclonal plasmacytosis may be difficult in cases with not much bone marrow infiltration. Normal plasma cells express the antigens CD138, CD38, CD19, CD10 and D-related human leucocyte antigen (HLA-DR). Myelomatous plasma cells lack B lymphoid-associated markers and may express cell surface antigens associated with other haematopoietic lineages such as NCAM/CD56 (neural cell adhesion molecule). Recently, a monoclonal antibody, anti-CD56, has become available that can be used in fixed tissues embedded in paraffin, and it has been reported that osteoblastic cells of trabecular bone strongly express NCAM/CD56. We analysed NCAM molecule expression in 35 samples from patients with plasma cell disorders: 14 cases of MM, 16 cases of MGUS, and five cases of polyclonal plasmacytosis using immunohistochemistry in parallel in bone marrow core biopsies processed routinely and in bone marrow smears from the same patients. Of the MM samples 78% were CD56+ in smears and 92% positive in biopsies. We did not find strong CD56 expression in MGUS samples. One of five samples of polyclonal plasmacytosis was CD56+. A case was considered to be positive for CD56 expression if >50% of the CD138+ plasma cells expressed NCAM with an intensity on a par with that of the osteoblasts. We conclude that CD56 antibody is a very useful marker in the study of plasma cell proliferation in bone marrow biopsies and in bone marrow aspirates and is a great help in discriminating between MM, MGUS, and polyclonal plasmacytosis, especially in those cases with low infiltration. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results